Dempze Nancy E Buys 117 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Dempze Nancy E grew its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 7,180 shares of the pharmaceutical company’s stock after purchasing an additional 117 shares during the quarter. Vertex Pharmaceuticals makes up approximately 1.8% of Dempze Nancy E’s holdings, making the stock its 24th biggest holding. Dempze Nancy E’s holdings in Vertex Pharmaceuticals were worth $3,197,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of VRTX. Activest Wealth Management acquired a new stake in Vertex Pharmaceuticals during the 1st quarter worth approximately $25,000. Clal Insurance Enterprises Holdings Ltd raised its holdings in shares of Vertex Pharmaceuticals by 450.0% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 45 shares during the last quarter. Flaharty Asset Management LLC bought a new position in shares of Vertex Pharmaceuticals in the first quarter valued at $32,000. American National Bank & Trust grew its stake in shares of Vertex Pharmaceuticals by 515.4% in the second quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock valued at $36,000 after buying an additional 67 shares in the last quarter. Finally, University of Texas Texas AM Investment Management Co. bought a new position in shares of Vertex Pharmaceuticals in the first quarter valued at $46,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Trading Up 2.6%

NASDAQ VRTX opened at $421.15 on Thursday. The firm has a market capitalization of $107.98 billion, a P/E ratio of 30.10 and a beta of 0.43. The business has a fifty day simple moving average of $395.83 and a 200 day simple moving average of $440.97. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The firm had revenue of $2.94 billion during the quarter, compared to analyst estimates of $2.90 billion. During the same period last year, the firm posted ($12.83) EPS. The business’s revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on VRTX shares. Evercore ISI reduced their price objective on shares of Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating for the company in a research report on Thursday, September 11th. Leerink Partners raised shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and cut their price objective for the stock from $458.00 to $456.00 in a research report on Thursday, September 25th. UBS Group set a $553.00 price objective on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Wall Street Zen downgraded Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 22nd. Finally, Morgan Stanley set a $439.00 price objective on Vertex Pharmaceuticals and gave the company an “equal weight” rating in a research note on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $494.43.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs purchased 5,000 shares of the company’s stock in a transaction dated Wednesday, August 6th. The stock was purchased at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the transaction, the director owned 45,000 shares in the company, valued at $17,535,600. The trade was a 12.50% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.